WO2006054722A1 - 遺伝子を用いた熱不安定性フェノタイプ症のリスク診断法 - Google Patents
遺伝子を用いた熱不安定性フェノタイプ症のリスク診断法 Download PDFInfo
- Publication number
- WO2006054722A1 WO2006054722A1 PCT/JP2005/021294 JP2005021294W WO2006054722A1 WO 2006054722 A1 WO2006054722 A1 WO 2006054722A1 JP 2005021294 W JP2005021294 W JP 2005021294W WO 2006054722 A1 WO2006054722 A1 WO 2006054722A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chain
- dod
- hadhb
- snp
- patients
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 26
- 201000010099 disease Diseases 0.000 title claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 title claims description 75
- 108090000790 Enzymes Proteins 0.000 claims abstract description 75
- 102000004190 Enzymes Human genes 0.000 claims abstract description 74
- 230000000694 effects Effects 0.000 claims abstract description 54
- 208000032274 Encephalopathy Diseases 0.000 claims abstract description 27
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 19
- 201000007981 Reye syndrome Diseases 0.000 claims abstract description 9
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 8
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- 150000002576 ketones Chemical class 0.000 claims abstract description 8
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 8
- 230000009385 viral infection Effects 0.000 claims abstract description 8
- 208000010370 Adenoviridae Infections Diseases 0.000 claims abstract description 6
- 206010060931 Adenovirus infection Diseases 0.000 claims abstract description 6
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims abstract description 6
- 201000005807 Japanese encephalitis Diseases 0.000 claims abstract description 6
- 241000710842 Japanese encephalitis virus Species 0.000 claims abstract description 6
- 208000011200 Kawasaki disease Diseases 0.000 claims abstract description 6
- 206010061494 Rhinovirus infection Diseases 0.000 claims abstract description 6
- 208000011589 adenoviridae infectious disease Diseases 0.000 claims abstract description 6
- 201000004792 malaria Diseases 0.000 claims abstract description 6
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims abstract description 6
- 230000027756 respiratory electron transport chain Effects 0.000 claims abstract description 6
- 201000005404 rubella Diseases 0.000 claims abstract description 6
- 208000034972 Sudden Infant Death Diseases 0.000 claims abstract description 5
- 206010042440 Sudden infant death syndrome Diseases 0.000 claims abstract description 5
- 230000002407 ATP formation Effects 0.000 claims abstract description 4
- 229960004203 carnitine Drugs 0.000 claims abstract description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims abstract 2
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 claims description 77
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims description 66
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims description 52
- 102100029103 3-ketoacyl-CoA thiolase Human genes 0.000 claims description 49
- 101000841262 Homo sapiens 3-ketoacyl-CoA thiolase Proteins 0.000 claims description 49
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 48
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 48
- 108700028369 Alleles Proteins 0.000 claims description 46
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims description 42
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 claims description 42
- 102100027262 Electron transfer flavoprotein subunit beta Human genes 0.000 claims description 35
- 101001057122 Homo sapiens Electron transfer flavoprotein subunit beta Proteins 0.000 claims description 35
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 claims description 34
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 29
- 102100031804 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial Human genes 0.000 claims description 20
- 101000920874 Homo sapiens Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial Proteins 0.000 claims description 20
- 206010022000 influenza Diseases 0.000 claims description 20
- 208000014644 Brain disease Diseases 0.000 claims description 18
- 238000004458 analytical method Methods 0.000 claims description 16
- 108010078791 Carrier Proteins Proteins 0.000 claims description 15
- 230000002438 mitochondrial effect Effects 0.000 claims description 15
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 claims description 14
- 108010000775 Hydroxymethylglutaryl-CoA synthase Proteins 0.000 claims description 13
- 206010014599 encephalitis Diseases 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 11
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 claims description 9
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 claims description 9
- 230000003647 oxidation Effects 0.000 claims description 9
- 102100030695 Electron transfer flavoprotein subunit alpha, mitochondrial Human genes 0.000 claims description 8
- 101001010541 Homo sapiens Electron transfer flavoprotein subunit alpha, mitochondrial Proteins 0.000 claims description 8
- 101001047912 Homo sapiens Hydroxymethylglutaryl-CoA lyase, mitochondrial Proteins 0.000 claims description 8
- 102100024004 Hydroxymethylglutaryl-CoA lyase, mitochondrial Human genes 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 230000037149 energy metabolism Effects 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims description 6
- 102000005870 Coenzyme A Ligases Human genes 0.000 claims description 6
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 claims description 6
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 claims description 6
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 claims description 6
- 102000002932 Thiolase Human genes 0.000 claims description 6
- 108060008225 Thiolase Proteins 0.000 claims description 6
- 102000054766 genetic haplotypes Human genes 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 108010068197 Butyryl-CoA Dehydrogenase Proteins 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 5
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 claims description 5
- 102000010821 Solute Carrier Family 22 Member 5 Human genes 0.000 claims description 5
- 230000004129 fatty acid metabolism Effects 0.000 claims description 5
- 210000003470 mitochondria Anatomy 0.000 claims description 5
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 5
- QRDZSRWEULKVNW-UHFFFAOYSA-N 6-hydroxy-2-oxo-1h-quinoline-4-carboxylic acid Chemical compound C1=C(O)C=C2C(C(=O)O)=CC(=O)NC2=C1 QRDZSRWEULKVNW-UHFFFAOYSA-N 0.000 claims description 4
- 241000219357 Cactaceae Species 0.000 claims description 4
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims description 4
- 102100021822 Enoyl-CoA hydratase, mitochondrial Human genes 0.000 claims description 4
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 4
- 108090000364 Ligases Proteins 0.000 claims description 4
- 108010066953 Mitochondrial Trifunctional Protein Proteins 0.000 claims description 4
- 102000018738 Mitochondrial Trifunctional Protein Human genes 0.000 claims description 4
- 108030005950 Short-chain-enoyl-CoA hydratases Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000001963 scanning near-field photolithography Methods 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 101100451261 Caenorhabditis elegans hmgs-1 gene Proteins 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010089760 Electron Transport Complex I Proteins 0.000 claims description 3
- 102000008013 Electron Transport Complex I Human genes 0.000 claims description 3
- 108010076322 Electron Transport Complex II Proteins 0.000 claims description 3
- 102000011687 Electron Transport Complex II Human genes 0.000 claims description 3
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 3
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 3
- 238000011529 RT qPCR Methods 0.000 claims description 3
- 108091006422 SLC25A20 Proteins 0.000 claims description 3
- 108010038615 Solute Carrier Family 22 Member 5 Proteins 0.000 claims description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims description 2
- 108091006515 Anion channels Proteins 0.000 claims description 2
- 102000037829 Anion channels Human genes 0.000 claims description 2
- 241001327534 Bunites Species 0.000 claims description 2
- 101710147349 Carnitine transporter Proteins 0.000 claims description 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 claims description 2
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 claims description 2
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims description 2
- 102000003939 Membrane transport proteins Human genes 0.000 claims description 2
- 108090000301 Membrane transport proteins Proteins 0.000 claims description 2
- 101710118206 Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 2
- 108091006736 SLC22A5 Proteins 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims 2
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 1
- 239000004071 soot Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 13
- 206010037660 Pyrexia Diseases 0.000 abstract description 9
- 231100000518 lethal Toxicity 0.000 abstract description 2
- 230000001665 lethal effect Effects 0.000 abstract description 2
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 description 60
- 238000003745 diagnosis Methods 0.000 description 23
- 208000021760 high fever Diseases 0.000 description 16
- 102200140344 rs1799821 Human genes 0.000 description 16
- 206010071602 Genetic polymorphism Diseases 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 12
- 101000839020 Homo sapiens Hydroxymethylglutaryl-CoA synthase, mitochondrial Proteins 0.000 description 10
- 102100028889 Hydroxymethylglutaryl-CoA synthase, mitochondrial Human genes 0.000 description 10
- 208000034486 Multi-organ failure Diseases 0.000 description 10
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 206010064571 Gene mutation Diseases 0.000 description 7
- 208000010718 Multiple Organ Failure Diseases 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- -1 ETFA Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000012252 genetic analysis Methods 0.000 description 5
- 102200141375 rs1799822 Human genes 0.000 description 5
- 206010048962 Brain oedema Diseases 0.000 description 4
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 208000006752 brain edema Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000020470 nervous system symptom Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 101710152982 Transcriptional enhancer factor TEF-4 Proteins 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid group Chemical group C(CCCC(=O)O)(=O)O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 208000002091 Febrile Seizures Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102100035146 Transcriptional enhancer factor TEF-4 Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 208000022602 disease susceptibility Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 230000008642 heat stress Effects 0.000 description 2
- 208000016245 inborn errors of metabolism Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 108010015052 miniplasmin Proteins 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 102200052146 rs2230178 Human genes 0.000 description 2
- 102200147393 rs2286963 Human genes 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 101150100859 45 gene Proteins 0.000 description 1
- 101100004986 Arabidopsis thaliana CAD3 gene Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005908 Body temperature conditions Diseases 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
- 102100027947 Carnitine O-palmitoyltransferase 1, muscle isoform Human genes 0.000 description 1
- 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000002269 Cytochrome P-450 CYP2C9 Human genes 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010079426 Electron-Transferring Flavoproteins Proteins 0.000 description 1
- 102000012737 Electron-Transferring Flavoproteins Human genes 0.000 description 1
- 101150043805 HADHA gene Proteins 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 101000859574 Homo sapiens Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 description 1
- 101000839025 Homo sapiens Hydroxymethylglutaryl-CoA synthase, cytoplasmic Proteins 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000755720 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Palmitoyltransferase akr1 Proteins 0.000 description 1
- 101001063357 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Palmitoyltransferase erf2 Proteins 0.000 description 1
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
- 208000007758 Odonto-onycho-dermal dysplasia Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 108091006688 Organic zwitterions/cation transporters Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- ZBQPJUMVWHDCRQ-UHFFFAOYSA-N SSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSS ZBQPJUMVWHDCRQ-UHFFFAOYSA-N 0.000 description 1
- OMGVLZMIEYQVLH-UHFFFAOYSA-N SSSSSSSSSSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSSSSSSSSSS OMGVLZMIEYQVLH-UHFFFAOYSA-N 0.000 description 1
- RDGPZDPSLYRRDM-UHFFFAOYSA-N SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS RDGPZDPSLYRRDM-UHFFFAOYSA-N 0.000 description 1
- JERLMHAZQDSGAC-UHFFFAOYSA-N SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS JERLMHAZQDSGAC-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000004962 Voltage-dependent anion channels Human genes 0.000 description 1
- 108090001129 Voltage-dependent anion channels Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 101150043789 cpt2 gene Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 125000004050 enoyl group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 231100000089 gene mutation induction Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009220 hypothermia therapy Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220136932 rs1049987 Human genes 0.000 description 1
- 102220139268 rs1056471 Human genes 0.000 description 1
- 102200140343 rs2229291 Human genes 0.000 description 1
- 102220069102 rs2229292 Human genes 0.000 description 1
- 102220028780 rs2303893 Human genes 0.000 description 1
- 102220028783 rs3839049 Human genes 0.000 description 1
- 102220055372 rs6145976 Human genes 0.000 description 1
- 102220139221 rs7260 Human genes 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002588053A CA2588053A1 (en) | 2004-11-19 | 2005-11-18 | Method of diagnosing the risk of thermolabile phenotype diseases by using gene |
US11/791,079 US20080187918A1 (en) | 2004-11-19 | 2005-11-18 | Method of Diagnosing the Risk of Thermolabile Phenotype Diseases by Using Gene |
EP05806833A EP1829977A4 (en) | 2004-11-19 | 2005-11-18 | METHOD FOR DIAGNOSING THE RISK OF DISEASES CAUSED BY A THERMOLABILE PHENOTYPE USING A GENE |
JP2006545182A JPWO2006054722A1 (ja) | 2004-11-19 | 2005-11-18 | 遺伝子を用いた熱不安定性フェノタイプ症のリスク診断法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004335966 | 2004-11-19 | ||
JP2004-335958 | 2004-11-19 | ||
JP2004-335966 | 2004-11-19 | ||
JP2004335958 | 2004-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006054722A1 true WO2006054722A1 (ja) | 2006-05-26 |
Family
ID=36407258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/021294 WO2006054722A1 (ja) | 2004-11-19 | 2005-11-18 | 遺伝子を用いた熱不安定性フェノタイプ症のリスク診断法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080187918A1 (ja) |
EP (1) | EP1829977A4 (ja) |
JP (1) | JPWO2006054722A1 (ja) |
KR (1) | KR20070090929A (ja) |
CA (1) | CA2588053A1 (ja) |
WO (1) | WO2006054722A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013035209A1 (ja) | 2011-09-05 | 2013-03-14 | 株式会社ポーラファルマ | Etfbの細胞異常増殖への適用方法及び異常増殖抑制剤 |
JP2018038417A (ja) * | 2012-07-17 | 2018-03-15 | カウンシル,インコーポレーテッド | 遺伝的変異を検出するためのシステムおよび方法 |
-
2005
- 2005-11-18 JP JP2006545182A patent/JPWO2006054722A1/ja active Pending
- 2005-11-18 EP EP05806833A patent/EP1829977A4/en not_active Withdrawn
- 2005-11-18 KR KR1020077013790A patent/KR20070090929A/ko not_active Application Discontinuation
- 2005-11-18 CA CA002588053A patent/CA2588053A1/en not_active Abandoned
- 2005-11-18 WO PCT/JP2005/021294 patent/WO2006054722A1/ja active Application Filing
- 2005-11-18 US US11/791,079 patent/US20080187918A1/en not_active Abandoned
Non-Patent Citations (7)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013035209A1 (ja) | 2011-09-05 | 2013-03-14 | 株式会社ポーラファルマ | Etfbの細胞異常増殖への適用方法及び異常増殖抑制剤 |
KR20140064913A (ko) | 2011-09-05 | 2014-05-28 | 가부시키가이샤 폴라 파마 | Etfb의 세포 이상증식에 대한 적용 방법 및 이상증식 억제제 |
US9562912B2 (en) | 2011-09-05 | 2017-02-07 | Pola Pharma Inc. | Method of identifying abnormal cells by expression levels of ETFB |
JP2018038417A (ja) * | 2012-07-17 | 2018-03-15 | カウンシル,インコーポレーテッド | 遺伝的変異を検出するためのシステムおよび方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006054722A1 (ja) | 2008-06-05 |
EP1829977A4 (en) | 2009-07-01 |
CA2588053A1 (en) | 2006-05-26 |
EP1829977A1 (en) | 2007-09-05 |
KR20070090929A (ko) | 2007-09-06 |
US20080187918A1 (en) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kirby et al. | NDUFS6 mutations are a novel cause of lethal neonatal mitochondrial complex I deficiency | |
Muise et al. | NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2 | |
Muise et al. | Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn’s disease | |
Pinney et al. | Dominant form of congenital hyperinsulinism maps to HK1 region on 10q | |
Yotsumoto et al. | Clinical and molecular investigations of Japanese cases of glutaric acidemia type 2 | |
JP2008516595A (ja) | 急性心筋梗塞を発症する危険度を測定する方法とキット | |
Laddha et al. | Tumor necrosis factor B (TNFB) genetic variants and its increased expression are associated with vitiligo susceptibility | |
US20130136720A1 (en) | Methods of using fut2 genetic variants to diagnose crohn's disease | |
JP2014097060A (ja) | 2型糖尿病の遺伝的感受性変異体 | |
Opdal et al. | Possible role of mtDNA mutations in sudden infant death | |
Ran et al. | Rare variants in SLC6A4 cause susceptibility to major depressive disorder with suicidal ideation in Han Chinese adolescents and young adults | |
Aka et al. | Risk of type 2 diabetes mellitus and cardiovascular complications in KCNJ11, HHEX and SLC30A8 genetic polymorphisms carriers: a case-control study | |
EP1852505B1 (en) | Mutations in ion channels | |
Bouzidi et al. | Association between MDR1 gene polymorphisms and the risk of Crohn’s disease in a cohort of Algerian pediatric patients | |
WO2006054722A1 (ja) | 遺伝子を用いた熱不安定性フェノタイプ症のリスク診断法 | |
US20100167285A1 (en) | Methods and agents for evaluating inflammatory bowel disease, and targets for treatment | |
Shi et al. | Cyclooxygenase‐2 gene polymorphisms in an Australian population: association of the− 1195G> A promoter polymorphism with mild asthma | |
Murthy et al. | Significant association of MTHFD1 1958G> A single nucleotide polymorphism with nonsyndromic cleft lip and palate in Indian population | |
EP1749891A1 (en) | Method and device for the in vitro detection of polycystic ovarian syndrome (pcos) and pathologies involving cardiovascular risk | |
Taqddus et al. | Association of endothelial nitric oxide synthase (eNOS) gene polymorphism (Glu 298 Asp) with coronary artery disease in subjects from Multan, Pakistan. | |
JP5904501B2 (ja) | 2型糖尿病の検出方法 | |
Al-Isawi et al. | Association of CTLA-4 (+ 49A/G) gene Polymorphism with type 1 diabetes mellitus in Iraqi children | |
WO2015086913A1 (en) | Methods for detection of the risk of obesity, the metabolic syndrome and diabetes | |
Masamune et al. | Variants in the UBR1 gene are not associated with chronic pancreatitis in Japan | |
US20130274132A1 (en) | Genetic Modifiers of Cystic Fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006545182 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2588053 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11791079 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580039863.9 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005806833 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077013790 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005806833 Country of ref document: EP |